Vynleads (VYND) 10-K 7 Apr 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Apr. 02, 2021
Document And Entity Information
Entity Registrant Name	Vynleads, Inc.
Entity Central Index Key	0001745078
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Is Entity Emerging Growth Company?	true
Entity Shell Company	false
Elected Not To Use the Extended Transition Period	false
Entity Well Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Common Stock, Shares Outstanding		11,599,830
Entity Public Float		$ 0
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Auditor Attestation Flag	false
Entity Incorporation State Country Name	DE
Entity File Number	333-227499

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current Assets:
Cash	$ 7,229	$ 63,395
Accounts Receivable	635	635
Holdback Receivable from merchant, net of reserve for refunds of $42 and $3,111, respectively	16,929	45,284
Prepaid Expenses and other current assets	13,206	3,081
Total current assets	37,999	112,395
Total assets	37,999	112,395
Current Liabilities:
Accounts payable and accrued expenses	256,784	172,757
Notes Payable	122,575	75,000
Total current liabilities	379,359	247,757
Notes Payable, net of current	8,925
Total liabilities	388,284	247,757
Commitments and contingencies (See Note 8)
Stockholders' deficit:
Preferred stock; $0.0001 par value; 5,000,000 shares authorized, no shares issued and outstanding, respectively
Common stock; $0.0001 par value; 50,000,000 shares authorized; 11,599,830 shares and 11,399,830 shares issued and outstanding, respectively	1,160	1,140
Additional paid in capital	1,364,252	1,199,565
Accumulated deficit	(1,715,697)	(1,336,067)
Total stockholders' deficit	(350,285)	(135,362)
Total liabilities and stockholders' deficit	$ 37,999	$ 112,395

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Refunds	$ 42	$ 3,111
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, share issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	11,599,830	11,399,830
Common stock, shares outstanding	11,599,830	11,399,830

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue, net of refunds and chargebacks	$ 48,262	$ 396,691
Cost and Expenses:
Cost of Revenue	56,708	179,066
Advertising	895	238,002
Selling, general and administrative expense	362,947	278,216
Total costs and expenses	420,550	695,284
Loss from operations	(372,288)	(298,593)
Other income	2,000
Interest expense	(8,188)	(3,416)
Net loss before provision for income taxes	(378,476)	(302,009)
Income tax expense	(1,154)	(1,059)
Net loss	$ (379,630)	$ (303,068)
Net loss per common share, basic and diluted	$ (0.03)	$ (0.03)
Weighted average common shares outstanding, basic and diluted	11,469,717	11,399,830

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Additional paid-in capital [Member]	Accumulated deficit [Member]	Total
Balance at Dec. 31, 2018	$ 1,140	$ 1,082,552	$ (1,032,999)	$ 50,693
Balance, shares at Dec. 31, 2018	11,399,830
Stock-based compensation		571		571
Capital Contribution		116,442		116,442
Net Loss			(303,068)	(303,068)
Balance at Dec. 31, 2019	$ 1,140	1,199,565	(1,336,067)	$ (135,362)
Balance, shares at Dec. 31, 2019	11,399,830			11,399,830
Common Stock Issued for Services	$ 20	44,980		$ 45,000
Common Stock Issued for Services Shares	200,000
Stock-based compensation		224		224
Capital Contribution		119,483		119,483
Net Loss			(379,630)	(379,630)
Balance at Dec. 31, 2020	$ 1,160	$ 1,364,252	$ (1,715,697)	$ (350,285)
Balance, shares at Dec. 31, 2020	11,599,830			11,599,830

Statement of Cash Flows

Statement of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (379,630)	$ (303,068)
Adjustments to reconcile net loss to net cash flows used in operating activities
Stock-based compensation	39,599	571
Capital contribution from CEO	119,483	116,442
Changes in operating assets and liabilities and other, net	107,882	153,365
Net cash flows used in operating activities	(112,666)	(32,690)
Cash flows from financing activities:
Proceeds from notes payable	56,500	75,000
Net cash flows provided by financing activities	56,500	75,000
Net (decrease) increase in cash	(56,166)	42,310
Cash at beginning of year	63,395	21,085
Cash at end of year	7,229	63,395
Supplemental disclosure of cash flow information:
Income taxes paid	1,555	1,140
Interest paid	5,602	3,416
Supplemental for non-cash investing and financing activities:
Stock issued for prepaid consulting	$ 5,625

Business

Business	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business	1. Business Vynleads, Inc. (“Vynleads”) was incorporated as a Delaware corporation on July 15, 2015. We are a provider of health and wellness information principally targeted to people who are pre-diabetes or who have type 2 diabetes. We provide information to our customers who are seeking to make healthy choices by providing clear, generic blueprints, education, resources, and support. Our core product is our proprietary Lifestyle Blueprint, a digital guide that provides dietary recommendations for a very low calorie eight-week diet together with information focusing on what, how and how much a person eats, nutritional information and how a person’s body does and does not use food to enable our customers to continue leading a more successful lifestyle. We also offer nutritional supplements and monthly subscriptions to our proprietary newsletter which covers a wide variety of healthy living-related topics. Our corporate headquarters are located in Rock Hill, South Carolina.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2020
Going Concern
Going Concern	2. Going Concern Our financial statements have been presented on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since July 15, 2015, the date of our inception, we have experienced recurring operating losses and negative operating cash flows, and have financed our recent working capital requirements primarily through the issuance of debt. During the years ended December 31, 2020 and 2019, we have reported net losses of $379,630 and $303,068, respectively. As of December 31, 2020, our working capital deficit was $341,360, our accumulated deficit was $1,715,697, and we had cash used in operations of $112,666. As a result, management believes that there is substantial doubt about our ability to continue as a going concern. Despite our current sales, expense, cash flow projections, and aggregate cash and holdback receivable from our merchant, net of reserve for refunds, of $16,929, we will require substantial funds to expand service and product offerings into additional areas, market and promote our services and product offerings; and develop and grow our infrastructure and corporate organization. Our capital requirements depend on numerous factors, including but not limited to our ability to generate sufficient revenues to pay our operating expenses. Our ability to meet our current and projected obligations depends on our ability to generate sufficient sales and to control expenses and will require that we seek additional capital through private and/or public financing sources. There can be no assurances that we will achieve our forecasted financial results or that we will be able to raise additional capital to operate our business. Any such failure would have a material adverse impact on our liquidity and financial condition and could force us to curtail or discontinue operations entirely and could require us to file for protection under bankruptcy laws. These conditions raise substantial doubt as to our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome from this uncertainty.

Summary of Critical Accounting

Summary of Critical Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Critical Accounting Policies	3. Summary of Critical Accounting Policies Accounting Principles The financial statements and accompanying notes are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Use of Accounting Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We believe that judgement is involved in determining our reserve for refunds, our holdback reserve, and valuation of stock-based compensation. We evaluate our estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the Financial Statements. Cash Cash includes cash on hand, is deposited at one area bank and may exceed federally insured limits at times. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The carrying amounts reported in the balance sheets for cash and cash equivalents approximate their fair value. Holdback Receivable Holdback receivable includes a merchant holdback net of a reserve for returns, which reserve is $42 and $3,111 as of December 31, 2020 and 2019, respectively. Revenue Recognition The Company accounts for revenue in accordance with Accounting Standard Codification (“ASC”) Topic 606. Revenues are recognized when the Company satisfies a performance obligation by transferring control of the promised goods or services to our customers at a point in time, in an amount specified in the contract with our customer and that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company also assesses our customer’s ability and intention to pay, which is based on a variety of factors including our customer’s historical payment experience and financial condition. We generate revenues primarily from (i) internet content subscriptions and (ii) sales of nutritional supplements. Revenues are recognized upon the acceptance of subscription membership or shipment of nutritional supplements, provided that an order has been received or a contract executed, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable and collection is deemed reasonably assured. If uncertainties regarding customer acceptance exist, we recognize revenues when those uncertainties are resolved, and title has been transferred to the customer. Amounts collected or billed prior to satisfying the above revenue recognition criteria are recorded as deferred revenue. Our percentages of revenue by type for years ended December 31, 2020 and 2019 are as follows: Year ended December 31, 2020 2019 Internet content subscriptions 15.2 % 43.7 % Nutritional supplements 84.8 % 56.3 % Shipping and Handling Costs We include shipping and handling fees billed to customers as revenue and shipping and handling costs for shipments to customers as cost of revenue. Advertising Costs Advertising costs for the years ended December 31, 2020 and 2019 were $895 and $238,002, respectively. Advertising costs are expensed as incurred or at the first time the advertising activity takes place. Loss Per Share Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income (loss) that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were excluded from the diluted loss per share calculations because the effect would be antidilutive or the options and warrants exercise prices were greater than the average market price of the common shares, were 585,766 shares for the years ended December 31, 2020 and 2019. Income Taxes The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate this tax position on a quarterly basis. We also accrue for potential interest and penalties, if applicable, related to unrecognized tax benefits in income tax expense. Stock-Based Compensation We account for stock based instruments issued to employees and non-employees for services in accordance with Accounting Standard Codification (“ASC”) Topic 718. Stock-based compensation is measured at the grant date based on the estimated fair value of the award and is recognized as an expense over the requisite service period. Accordingly, the Black-Scholes option pricing model is utilized to derive an estimated fair value. The Black-Scholes pricing model requires the consideration of the following six variables for purposes of estimating fair value: · the stock option exercise price; · the expected term of the option; · the grant date price of our common stock, which is issuable upon exercise of the option; · the expected volatility of our common stock; · the expected dividends on our common stock (we do not anticipate paying dividends in the foreseeable future); and · the risk-free interest rate for the expected option term. Expected Dividends. Expected Volatility. Risk-Free Interest Rate. Expected Term. Grant Date Price of Common Stock. Fair Value of Financial Instruments We follow Accounting Standards Codification 820-10 (“ASC 820-10”), “Fair Value Measurements and Disclosures,” The hierarchy established under ASC 820-10 gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820-10 are described below: Level 1 - Pricing inputs are quoted prices available in active markets for identical investments as of the reporting date. As required by ASC 820-10, we do not adjust the quoted price for these investments, even in situations where we hold a large position and a sale could reasonably impact the quoted price. Level 2 - Pricing inputs are quoted prices for similar investments, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to these investments. Level 3 - Pricing inputs are unobservable for the investment, that is, inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability. Level 3 includes investments that are supported by little or no market activity. The carrying amounts of our cash, holdback receivable, prepaid expense and other current asset, accounts payable and accrued expenses approximate their fair values due to their short-term maturities as of December 31, 2020 and 2019. Recent Accounting Pronouncements We have evaluated all issued but not yet effective accounting pronouncements and determined that, other than the following, they are either immaterial or not relevant to us. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 provide for simplified accounting to several income tax situations and removal of certain accounting exceptions. The ASU is effective for annual reporting periods beginning after December 15, 2020, including interim periods within those periods. We do not expect the impact of the adoption of ASU 2019-12 to have a material effect on the Company's results of operations, cash flows or financial condition.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	4. Related Party Transactions During the years ended December 31, 2020 and 2019, we paid Mr. Bezusov $2,000 and $2,500, respectively, in consulting fees pursuant to a verbal agreement with him. We are not a party to an employment agreement with Mr. Bezusov and the compensation he is paid for his services is determined by the board of directors. During the years ended December 31, 2020 and 2019, Mr. Mannine voluntarily agreed to waive all cash due and any related accruals. The salary forgiven for the years ended December 31, 2020 and 2019 of $116,443 and $116,442 is treated as in-kind contribution of service and reflected as contributed capital in the financial statements (See Notes 8 and 10). During the year ended December 31, 2020, Mr. Mannine personally paid $3,040 of company expenses. This is reflected as contributed capital in the financial statements. On May 21, 2018, we entered into an Amended and Restated Strategic Financing & Corporate Development Agreement with CRG which was amended and restated an earlier agreement entered into in October 2017. We have engaged this company to serve as our non-exclusive strategic financing and corporate development services provider and to render certain advice and services to us as we may reasonably request concerning equity or debt financings, strategic planning, merger and acquisition possibilities, and business development activities. The scope of services under this agreement also includes introducing us to one or more non-U.S. persons, as that term is defined in Regulation S under the Securities Act, in connection with possible debt or equity financings or potential lenders. The initial term of the agreement expired in May 2019, but pursuant to the terms of the agreement, renews automatically for one-year periods unless notice of non-renewal is provided by either party at least 30 days prior to the renewal term commencement. The agreement was renewed in May 2020. As compensation under the terms of this agreement, we agreed to pay CRG Finance AG certain fees for transactions which are consummated during the term of the agreement and for a one year period following the termination of the agreement, including: · a fee equal to 7% of the proceeds received by us plus a warrant exercisable into 7% of the shares of our common stock at the offering price of our shares for sales by us of equity or equity-linked securities to non-U.S. Persons introduced to us by CRG Finance AG; · a fee equal to 1% of the total gross cash proceeds or non-cash consideration received by us, together with a five year warrant exercisable into 1% of the securities issued or to be issued by us in a business combination with a non-U.S. person first introduced to us by CRG Finance AG; · a fee equal to 1% of consideration received by us in any debt financing not convertible into equity, including, but not limited to, a revolving credit line or credit enhancement instrument, including on an insured or guarantee basis, with a non-U.S. Person first introduced to us by CRG Finance AG; and · a fee equal to 2% of any revenue-producing contract, fee-sharing arrangement, licensing, royalty or similar agreement with a non-U.S. Person first introduced to us by CRG Finance AG. In addition to the foregoing fees, we have agreed to reimburse CRG Finance AG for its pre-approved out of pocket expenses it incurs under the terms of the agreement. The agreement contains customary confidentiality and indemnification provisions.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	5. Income Taxes For the year ended December 31, 2020 the provision for income taxes was As of December 31, 2020, we have net operating loss carryforwards of approximately 2020 2019 Tax Rate Tax Rate Taxes computed at statutory rate Federal $ (79,480 ) 21.00 % $ (63,411 ) 21.00 % State (14,950 ) 3.95 % (10,868 ) 3.95 % Total taxes at blended statutory rate $ (94,430 ) 24.95 % $ (74,279 ) 24.95 % Increase (decrease) resulting from: Effect of tax rate change — 0.00 % — 0.00 % Nondeductible expenses — 0.00 % — 0.00 % State income tax refund — 0.00 % — 0.00 % Other 3,318 -0.88 % (23,988 ) 8.06 % Change in valuation allowance 92,266 -24.38 % 99,326 -33.36 % Total income tax (benefit) expense $ 1,154 -0.31 % $ 1,059 -0.35 % The tax effect of significant components of our deferred tax assets and liabilities at December 31, 2020 and 2019, are as follows: 2020 2019 Deferred tax assets: Net operating loss carryforward $ 441,506 $ 347,699 Amortization of intangibles 8,317 9,149 Reserve for refunds 11 776 Stock compensation 3,774 3,718 Charitable contribution carryforward 3,355 3,355 Total deferred tax assets 456,963 364,697 Less: Valuation allowance (456,963 ) (364,697 ) Net deferred tax assets $ — $ — In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Because of our historical earnings history, the net deferred tax asset for 2020 has been reduced based on the amount deemed recoverable from the use of loss carrybacks. The change in the valuation allowance was an increase of $92,266 and $99,326 for the years ended December 31, 2020 and 2019, respectively.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable On November 18, 2019, the Company executed a note payable to an individual in the amount of $50,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. On May 14, 2020, $1,250 of accrued interest was paid. Accrued interest on On November 18, 2019, the Company executed a note payable to an individual in the amount of $25,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. Accrued interest on December 31, 2020 and 2019 is $1,380 and $140, respectively. This note is currently in default. On May 5, 2020, the Company received loan proceeds in the amount of $27,000 from Bank of America (the “Lender”) under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act), provides for loans to qualifying business for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loan matures on April 20, 2022 and bears an interest rate of 1.00% fixed per annum, payable monthly commencing on October 20, 2020. The loan is forgivable if the proceeds are used for eligible purposes. The Company used the entire loan amount for qualifying expenses. On October 27, 2020, the Company executed a note payable to an individual in the amount of $10,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. Accrued interest on December 31, 2020 is $90. On December 17, 2020, the Company executed a note payable to an individual in the amount of $19,500, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. Accrued interest on December 31, 2020 is $40.

Economic Injury Disaster Loan

Economic Injury Disaster Loan	12 Months Ended
	Dec. 31, 2020
Other Income and Expenses [Abstract]
Economic Injury Disaster Loan	7. Economic Injury Disaster Loan On April 14, 2020, the Company received a grant in the amount of $2,000 which does not have to be repaid from the SBA under its

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Employment Agreement On June 14, 2018, we entered into an employment agreement with Mr. Mannine pursuant to which he was engaged to serve as our Chief Executive Officer. The initial term of the agreement expires in June 2023, subject to successive automatic one- year renewals unless a non-renewal notice is received by either party at least 90 days prior to the expiration of the then current renewal term. Mr. Mannine’s compensation includes: · an annual base salary of $130,000, subject to an annual review with an increase of at least 5% per annum as determined by the board of directors; · an annual bonus as determined by the board of directors; · a grant of 10-year options to purchase 100,000 shares of our common stock at an exercise price of $0.225 per share which vest upon the effectiveness of a registration statement to be filed with the Securities and Exchange Commission; · participation in all benefit plans we may offer our employees; and · 20 paid vacation days annually. Mr. Mannine's employment agreement may be terminated, and he is entitled to certain payments upon such termination, as follows: · if we should terminate Mr. Mannine ’ “ ” · if Mr. Mannine ’ · if we should terminate Mr. Mannine for “cause,” or if he voluntarily terminates the agreement, he is entitled to receive his base salary only through the date of termination, and he is not be entitled to any other compensation for the calendar year during which the termination occurs or any subsequent calendar period, including, but not limited to, any annual bonus, if any, that has not already been paid. The employment agreement with Mr. Mannine contains customary confidentiality, non-compete and indemnification clauses. On September 21, 2020, Mr. Mannine agreed to voluntarily cancel the employment agreement. During the years ended December 31, 2020 and 2019, Mr. Mannine voluntarily agreed to waive all cash due and any related accruals. The salary forgiven for the years ended December 31, 2020 and 2019 of Commitments On May 21, 2018, we entered into an Amended and Restated Strategic Financing & Corporate Development Agreement with CRG which was amended and restated an earlier agreement entered into in October 2017. We have engaged this company to serve as our non-exclusive strategic financing and corporate development services provider and to render certain advice and services to us as we may reasonably request concerning equity or debt financings, strategic planning, merger and acquisition possibilities, and business development activities. The scope of services under this agreement also includes introducing us to one or more non-U.S. persons, as that term is defined in Regulation S under the Securities Act, in connection with possible debt or equity financings or potential lenders. The initial term of the agreement expired in May 2019, but pursuant to the terms of the agreement, renews automatically for one-year periods unless notice of non-renewal is provided by either party at least 30 days prior to the renewal term commencement. The agreement was renewed in May 2020. As compensation under the terms of this agreement, we agreed to pay CRG Finance AG certain fees for transactions which are consummated during the term of the agreement and for a one year period following the termination of the agreement, including: · a fee equal to 7% of the proceeds received by us plus a warrant exercisable into 7% of the shares of our common stock at the offering price of our shares for sales by us of equity or equity-linked securities to non-U.S. Persons introduced to us by CRG Finance AG; · a fee equal to 1% of the total gross cash proceeds or non-cash consideration received by us, together with a five year warrant exercisable into 1% of the securities issued or to be issued by us in a business combination with a non-U.S. person first introduced to us by CRG Finance AG; · a fee equal to 1% of consideration received by us in any debt financing not convertible into equity, including, but not limited to, a revolving credit line or credit enhancement instrument, including on an insured or guarantee basis, with a non-U.S. Person first introduced to us by CRG Finance AG; and · a fee equal to 2% of any revenue-producing contract, fee-sharing arrangement, licensing, royalty or similar agreement with a non-U.S. Person first introduced to us by CRG Finance AG. In addition to the foregoing fees, we have agreed to reimburse CRG Finance AG for its pre-approved out of pocket expenses it incurs under the terms of the agreement. The agreement contains customary confidentiality and indemnification provisions. On February 12, 2020, we entered a consulting agreement with Primoris Group Inc (“Primoris”). Primoris was issued 200,000 common shares at a fair value of $45,000 ($0.225 per share) on June 30, 2020. 100,000 shares are restricted from resale or transfer by Primoris per the consulting agreement until February 12, 2021. The consultant has an option to register 100,000 on any future registration statement. In addition to any restrictions imposed by the agreement, all the shares require an exemption for resale to the public. Under terms of the consulting agreement, we agree to pay Primoris $8,000 per month payable in advance of the month in which services are to be rendered as a consulting fee. Contingencies In April 2016, we entered into a Promotion and Royalty Agreement (the “Agreement”) with a consultant to obtain certain promotional services from him (the “Promoter”), including the use of his name and appearance. In consideration for the services rendered by the Promoter, we agreed to use commercially reasonable efforts to promote and sell a book authored by him (the “Book”) and to pay him a percentage of the sales of the Book after deductions for all direct costs of fulfilling such sales (the “Royalty”). During the course of 2017, the Promoter initiated a series of informal claims and filed unauthorized uniform commercial code financing statements (“UCC Liens”) in several states as liens against us and certain of our officers, directors, and founders, alleging non- payment for the Royalty amounts due under the Agreement. We dispute the Promoter’s claims and have determined that any and all amounts due to the Promoter under the Agreement have been paid in full. We have succeeded in removing certain of the UCC Liens and are pursuing action to remove the remaining unauthorized UCC Liens. We do not believe that the claims of the Promoter are valid in any respect.

Concentration of Credit Risk an

Concentration of Credit Risk and Major Customers and Suppliers	12 Months Ended
	Dec. 31, 2020
Risks and Uncertainties [Abstract]
Concentration of Credit Risk and Major Customers and Suppliers	9. Concentration of Credit Risk and Major Customers and Suppliers None of our revenues are concentrated with any single customer composing 10% or more of our total revenues. We purchase our inventory of herbal/natural supplements from one supplier. While we believe that we will be able to find a secondary supplier, there could be a manufacturing delay in the transition to a new supplier and such a supply interruption would materially impact our business for some period of time.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Equity (Deficit)	10. Stockholders’ Equity (Deficit) Our authorized capital stock consists of 50,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000 shares of blank check preferred stock, par value $0.0001 per share. As of December 31, 2020 and 2019, there are 11,599,830 and 11,399,830 shares of common stock outstanding, respectively and there are no shares of preferred stock issued and outstanding at either date. Contributed Capital On September 21, 2020, Mr. Mannine voluntarily agreed to cancel his employment agreement and waive all cash due and any related accruals. The salary forgiven for the year ended December 31, 2020 and 2019 of $116,443 and $116,442 is treated as in-kind contribution of service and reflected as contributed capital in the financial statements. During the year ended December 31, 2020, Mr. Mannine personally paid $3,040 of company expenses. This is reflected as contributed capital in the financial statements. Consulting Agreement On February 12, 2020, we entered a consulting agreement with Primoris Group Inc (“Primoris”). Primoris was issued 200,000 common shares at a fair value of $45,000 ($0.225 per share) on June 30, 2020. 100,000 shares are restricted from resale or transfer by Primoris per the consulting agreement until February 12, 2021. The consultant has an option to register 100,000 on any future registration statement. In addition to any restrictions imposed by the agreement, all the shares require an exemption for resale to the public. For the year ended December 31, 2020, we have recorded stock-based compensation of $39,375. As of December 31, 2020, $5,625 is recorded in prepaid expense related to the consulting agreement. Preferred Stock Our board of directors, without further stockholder approval, may issue preferred stock in one or more series from time to time and fix or alter the designations, relative rights, priorities, preferences, qualifications, limitations and restrictions of the shares of each series. The rights, preferences, limitations and restrictions of different series of preferred stock may differ with respect to dividend rates, amounts payable on liquidation, voting rights, conversion rights, redemption provisions, sinking fund provisions and other matters. Our board of directors may authorize the issuance of preferred stock, which ranks senior to our common stock for the payment of dividends and the distribution of assets on liquidation. In addition, our board of directors can fix limitations and restrictions, if any, upon the payment of dividends on both classes of our common stock to be effective while any shares of preferred stock are outstanding. Warrants On October 10, 2017, we entered into the Financing Agreement with CRG, as more fully described in Notes 4 and 8. In connection with the related equity financing as of December 31, 2017, CRG had earned 368,111 fully vested five-year warrants with an exercise price of $0.225. The related warrants were issued in January 2018. We determined that the warrant had an initial fair value of $34,405 and was recorded as a direct offering cost in Stockholders’ equity with a net effect of zero. We estimated the fair value of this warrant using the Black-Scholes option pricing model, based on the following assumptions: the recent cash offering price of $0.225 as the estimated fair value of the underlying common stock at the valuation measurement date; no dividend yield for all of the years; expected volatility of 45%; risk-free interest rate of 2.2% and an expected life of 5 years. During January 2018, as part of the Private Placement more fully described in Note 4, CRG earned an additional 17,655 fully vested common stock warrants with an exercise price of $0.225. These additional warrants were issued to CRG on January 30, 2018. We determined that the warrant had an initial fair value of $1,670 and was recorded as a direct offering cost in Stockholders’ equity with a net effect of zero. We estimated the fair value of this warrant using the Black-Scholes option pricing model, based on the following assumptions: the recent cash offering price of $0.225 as the estimated fair value of the underlying common stock at the valuation measurement date; no dividend yield for all of the years; expected volatility of 45%; risk-free interest rate of 2.51% and an expected life of 5 years. On March 8, 2018, we entered into an advisory agreement with a scientific advisor to provide certain services to us. Pursuant to the agreement, we issued 100,000 five-year common stock warrants at an exercise price of $0.90. Such warrants vest subject to certain milestones. As of December 31, 2020 and 2019, 100,000 and 66,666 of these warrants have vested. We determined that the warrant had an initial fair value of $1,905. We estimated the fair value of this warrant using the Black- Scholes option pricing model, based on the following assumptions: the recent cash offering price of $0.225 as the estimated fair value of the underlying common stock at the valuation measurement date; no dividend yield for all of the years; expected volatility of 45%; risk-free interest rate of 2.63% and an expected life of 5 years. During the years ended December 31, 2020 and 2019, we have recorded stock-based compensation expense of $224 and $571, respectively which is included in our selling, general and administrative expense on the accompanying Statements of Operations. As of December 31, 2020, the intrinsic value for warrants outstanding and exercisable is $144,662. The following table summarizes information about the warrants outstanding and exercisable as of December 31, 2020 and 2019: 2020 2019 Warrants Weighted Average Exercise Price Warrants Weighted Average Exercise Price Outstanding, beginning of year 485,766 $ 0.364 485,766 $ 0.364 Granted — — — — Exercised — — — — Forfeited — — — — Expired — — — — Outstanding, end of year 485,766 $ 0.364 485,766 $ 0.364 Exercisable, end of year 485,766 $ 0.364 452,432 $ 0.324 As of December 31, 2020 Warrants Outstanding Warrants Exercisable Range of Exercise Price Number Outstanding Remaining Average Contractual Life (In Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $0.225 -$0.90 485,766 2.10 $0.364 485,766 $0.364 As of December 31, 2019 Warrants Outstanding Warrants Exercisable Range of Exercise Price Number Outstanding Remaining Average Contractual Life (In Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $0.225 -$0.90 485,766 4.12 $0.364 452,432 $0.324

Stock Option Plan

Stock Option Plan	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock Option Plan	11. Stock Option Plan In December 2017 our board of directors adopted our 2017 Equity Incentive Plan, or the “2017 Plan.” Our stockholders ratified the 2017 Plan in December 2017. The purpose of the 2017 Plan is to encourage ownership in our company by our officers, directors, employees and consultants, and to incentivize and align the interests of the plan participants with the interests of our stockholders. We have reserved 1,100,000 shares of our common stock for issuance under the 2017 Plan. Grants pursuant to the 2017 Plan may be: i) incentive stock options; ii) non-statutory stock options; iii) stock awards, including shares of our common stock and stock units; and iv) stock appreciation rights. The board of directors or a committee of the board of directors administers the 2017 Plan. Presently, the 2017 Plan is administered by our board of directors. The term of each plan option and the manner in which it may be exercised is determined by the board of directors or a committee of the board of directors, provided that no option may be exercisable more than 10 years after the date of its grant and, in the case of an incentive option granted to an eligible employee owning more than 10% of the common stock, no more than five years after the date of the grant. The terms of grants or any other type of award under the plan are determined by the board of directors or committee of the board of directors at the time of grant. The 2017 Plan provides that the maximum value of any award during any calendar year cannot exceed $1,000,000. Any option granted under the plan must provide for an exercise price of not less than 100% of the fair market value of the underlying shares on the date of grant, but the exercise price of any ISO granted under the 2017 Plan to an eligible employee owning more than 10% of our outstanding common stock must not be less than 110% of fair market value on the date of the grant. The 2017 Plan further provides that with respect to ISOs the aggregate fair market value of the common stock underlying the options which are exercisable by any plan participant during any calendar year cannot exceed $100,000. Option awards may provide for the exercise by means of cash, consideration received by us under a broker-assisted sale and remittance program, cashless exercise, any other consideration legally permitted, or a combination of the foregoing. The 2017 Plan administrator may also determine the method of payment of the exercise price at the time the option is being exercised. Grants under the 2017 Plan are not transferrable. Generally, options which are exercisable at the date of the plan participant’s termination from our employment or severance of the relationship with our company must be exercised within three months of the termination date; the plan administrator may extend the exercise period of the option for a separated plan participant providing that the extended date does not go beyond the original expiration date of the option. Similarly, generally options which are exercisable at the date of the plan participant’s disability or death must be exercised within six months of the termination date in the event of the disability of the plan participant or 12 months following the plan participant’s death. In our discretion, any outstanding options held by a plan participant terminated for cause may be immediately cancelled. In the event there is a “change in control” of our company as defined in the 2017 Plan, as determined by the board of directors or the committee, we may in our discretion: i) provide for the assumption or substitution of, or adjustment (including to the number and type of shares and exercise or purchase price applicable) to, each outstanding award; ii) accelerate the vesting of options and terminate any restrictions on stock awards; and/or iii) provide for termination of awards as a result of the change in control on such terms and conditions as it deems appropriate, including providing for the cancellation of awards for a cash or other payment to the participant. The number of shares of our common stock underlying any outstanding but unexercised option and the exercise price of that option will be proportionally adjusted in the event of a stock split, stock combinations, dividends, and similar corporate events. On June 14, 2018, pursuant to the employment agreement with Mr. Mannine, more fully described in Note 8, we issued 100,000 stock options with an exercise price of $0.225. Such options fully vest upon the effectiveness of a registration statement on Form S-1. We determined that the options had an initial fair value of $13,221. We estimated the fair value of these options using the Black-Scholes option pricing model, based on the following assumptions: the recent cash offering price of $0.225 as the estimated fair value of the underlying common stock at the valuation measurement date; no dividend yield for all of the years; expected volatility of 45%; risk-free interest rate of 2.2% and an expected life of 10 years. We amortized the fair value over the period from their issuance on June 14, 2018 through December 7, 2018, the date on which the registration statement was declared effective. As of December 31, 2020, the intrinsic value for option outstanding and exercisable is $37,500. The following table summarizes information about stock options outstanding and exercisable as of as of December 31, 2020 and 2019: 2020 2019 Options Weighted Average Exercise Price Options Weighted Average Exercise Price Outstanding, beginning of year 100,000 $ 0.225 100,000 $ 0.225 Granted — — — — Exercised — — — — Forfeited — — — — Expired — — — — Outstanding, end of year 100,000 $ 0.225 100,000 $ 0.225 Exercisable, end of year 100,000 $ 0.225 100,000 $ 0.225 Options available for future grant, end of year 1,000,000 1,000,000 As of December 31, 2020 Options Outstanding Options Exercisable Range of Exercise Price Number Outstanding Remaining Average Contractual Life (In Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $0.225 100,000 7.93 $0.225 100,000 $0.225 As of December 31, 2019 Options Outstanding Options Exercisable Range of Exercise Price Number Outstanding Remaining Average Contractual Life (In Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $0.225 100,000 8.54 $0.225 100,000 $0.225

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Event	12. Subsequent Events On February 3, 2021, the Company executed a note payable to an individual in the amount of $10,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. On March 16, 2021, the Company executed a note payable to an individual in the amount of $15,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Summary of Critical Accountin_2

Summary of Critical Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Accounting Principles	Accounting Principles The financial statements and accompanying notes are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”).
Use of Accounting Estimates	Use of Accounting Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We believe that judgement is involved in determining our reserve for refunds, our holdback reserve, and valuation of stock-based compensation. We evaluate our estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the Financial Statements.
Cash	Cash Cash includes cash on hand, is deposited at one area bank and may exceed federally insured limits at times. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The carrying amounts reported in the balance sheets for cash and cash equivalents approximate their fair value.
Holdback Receivable	Holdback Receivable Holdback receivable includes a merchant holdback net of a reserve for returns, which reserve is $42 and $3,111 as of December 31, 2020 and 2019, respectively.
Revenue Recognition	Revenue Recognition The Company accounts for revenue in accordance with Accounting Standard Codification (“ASC”) Topic 606. Revenues are recognized when the Company satisfies a performance obligation by transferring control of the promised goods or services to our customers at a point in time, in an amount specified in the contract with our customer and that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company also assesses our customer’s ability and intention to pay, which is based on a variety of factors including our customer’s historical payment experience and financial condition. We generate revenues primarily from (i) internet content subscriptions and (ii) sales of nutritional supplements. Revenues are recognized upon the acceptance of subscription membership or shipment of nutritional supplements, provided that an order has been received or a contract executed, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable and collection is deemed reasonably assured. If uncertainties regarding customer acceptance exist, we recognize revenues when those uncertainties are resolved, and title has been transferred to the customer. Amounts collected or billed prior to satisfying the above revenue recognition criteria are recorded as deferred revenue. Our percentages of revenue by type for years ended December 31, 2020 and 2019 are as follows: Year ended December 31, 2020 2019 Internet content subscriptions 15.2 % 43.7 % Nutritional supplements 84.8 % 56.3 %
Shipping and Handling Costs	Shipping and Handling Costs We include shipping and handling fees billed to customers as revenue and shipping and handling costs for shipments to customers as cost of revenue.
Advertising Costs	Advertising Costs Advertising costs for the years ended December 31, 2020 and 2019 were $895 and $238,002, respectively. Advertising costs are expensed as incurred or at the first time the advertising activity takes place.
Loss Per Share	Loss Per Share Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income (loss) that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were excluded from the diluted loss per share calculations because the effect would be antidilutive or the options and warrants exercise prices were greater than the average market price of the common shares, were 585,766 shares for the years ended December 31, 2020 and 2019.
Income Taxes	Income Taxes The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate this tax position on a quarterly basis. We also accrue for potential interest and penalties, if applicable, related to unrecognized tax benefits in income tax expense.
Stock-Based Compensation	Stock-Based Compensation We account for stock based instruments issued to employees and non-employees for services in accordance with Accounting Standard Codification (“ASC”) Topic 718. Stock-based compensation is measured at the grant date based on the estimated fair value of the award and is recognized as an expense over the requisite service period. Accordingly, the Black-Scholes option pricing model is utilized to derive an estimated fair value. The Black-Scholes pricing model requires the consideration of the following six variables for purposes of estimating fair value: · the stock option exercise price; · the expected term of the option; · the grant date price of our common stock, which is issuable upon exercise of the option; · the expected volatility of our common stock; · the expected dividends on our common stock (we do not anticipate paying dividends in the foreseeable future); and · the risk-free interest rate for the expected option term. Expected Dividends. Expected Volatility. Risk-Free Interest Rate. Expected Term. Grant Date Price of Common Stock.
Fair Value of Financial Instruments	Fair Value of Financial Instruments We follow Accounting Standards Codification 820-10 (“ASC 820-10”), “Fair Value Measurements and Disclosures,” The hierarchy established under ASC 820-10 gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820-10 are described below: Level 1 - Pricing inputs are quoted prices available in active markets for identical investments as of the reporting date. As required by ASC 820-10, we do not adjust the quoted price for these investments, even in situations where we hold a large position and a sale could reasonably impact the quoted price. Level 2 - Pricing inputs are quoted prices for similar investments, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to these investments. Level 3 - Pricing inputs are unobservable for the investment, that is, inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability. Level 3 includes investments that are supported by little or no market activity. The carrying amounts of our cash, holdback receivable, prepaid expense and other current asset, accounts payable and accrued expenses approximate their fair values due to their short-term maturities as of December 31, 2020 and 2019.
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have evaluated all issued but not yet effective accounting pronouncements and determined that, other than the following, they are either immaterial or not relevant to us. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 provide for simplified accounting to several income tax situations and removal of certain accounting exceptions. The ASU is effective for annual reporting periods beginning after December 15, 2020, including interim periods within those periods. We do not expect the impact of the adoption of ASU 2019-12 to have a material effect on the Company's results of operations, cash flows or financial condition.

Summary of Critical Accountin_3

Summary of Critical Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Percentage of Revenue by Type	Our percentages of revenue by type for years ended December 31, 2020 and 2019 are as follows: Year ended December 31, 2020 2019 Internet content subscriptions 15.2 % 43.7 % Nutritional supplements 84.8 % 56.3 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Tax Rate Reconciliation	The reasons for these differences are: 2020 2019 Tax Rate Tax Rate Taxes computed at statutory rate Federal $ (79,480 ) 21.00 % $ (63,411 ) 21.00 % State (14,950 ) 3.95 % (10,868 ) 3.95 % Total taxes at blended statutory rate $ (94,430 ) 24.95 % $ (74,279 ) 24.95 % Increase (decrease) resulting from: Effect of tax rate change — 0.00 % — 0.00 % Nondeductible expenses — 0.00 % — 0.00 % State income tax refund — 0.00 % — 0.00 % Other 3,318 -0.88 % (23,988 ) 8.06 % Change in valuation allowance 92,266 -24.38 % 99,326 -33.36 % Total income tax (benefit) expense $ 1,154 -0.31 % $ 1,059 -0.35 %
Deferred Tax Assets and Liabilities	The tax effect of significant components of our deferred tax assets and liabilities at December 31, 2020 and 2019, are as follows: 2020 2019 Deferred tax assets: Net operating loss carryforward $ 441,506 $ 347,699 Amortization of intangibles 8,317 9,149 Reserve for refunds 11 776 Stock compensation 3,774 3,718 Charitable contribution carryforward 3,355 3,355 Total deferred tax assets 456,963 364,697 Less: Valuation allowance (456,963 ) (364,697 ) Net deferred tax assets $ — $ —

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Warrants Outstanding and Exercisable	The following table summarizes information about the warrants outstanding and exercisable as of December 31, 2020 and 2019: 2020 2019 Warrants Weighted Average Exercise Price Warrants Weighted Average Exercise Price Outstanding, beginning of year 485,766 $ 0.364 485,766 $ 0.364 Granted — — — — Exercised — — — — Forfeited — — — — Expired — — — — Outstanding, end of year 485,766 $ 0.364 485,766 $ 0.364 Exercisable, end of year 485,766 $ 0.364 452,432 $ 0.324
Warrants Outstanding and Exercisable by Range of Exercise Price	As of December 31, 2020 Warrants Outstanding Warrants Exercisable Range of Exercise Price Number Outstanding Remaining Average Contractual Life (In Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $0.225 -$0.90 485,766 2.10 $0.364 485,766 $0.364 As of December 31, 2019 Warrants Outstanding Warrants Exercisable Range of Exercise Price Number Outstanding Remaining Average Contractual Life (In Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $0.225 -$0.90 485,766 4.12 $0.364 452,432 $0.324

Stock Option Plan (Tables)

Stock Option Plan (Tables)	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Options Outstanding and Exercisable	The following table summarizes information about stock options outstanding and exercisable as of as of December 31, 2020 and 2019: 2020 2019 Options Weighted Average Exercise Price Options Weighted Average Exercise Price Outstanding, beginning of year 100,000 $ 0.225 100,000 $ 0.225 Granted — — — — Exercised — — — — Forfeited — — — — Expired — — — — Outstanding, end of year 100,000 $ 0.225 100,000 $ 0.225 Exercisable, end of year 100,000 $ 0.225 100,000 $ 0.225 Options available for future grant, end of year 1,000,000 1,000,000
Options Outstanding by Exercise Price Range	As of December 31, 2020 Options Outstanding Options Exercisable Range of Exercise Price Number Outstanding Remaining Average Contractual Life (In Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $0.225 100,000 7.93 $0.225 100,000 $0.225 As of December 31, 2019 Options Outstanding Options Exercisable Range of Exercise Price Number Outstanding Remaining Average Contractual Life (In Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $0.225 100,000 8.54 $0.225 100,000 $0.225

Going Concern (Details)

Going Concern (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Going Concern
Net loss	$ 379,630	$ 303,068
Accumulated deficit	1,715,697	1,336,067
Working capital deficit	341,360
Net cash flows used in operating activities	(112,666)	(32,690)
Holdback Receivable	$ 16,929	$ 45,284

Summary of Critical Accountin_4

Summary of Critical Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Refunds	$ 42	$ 3,111
Advertising	$ 895	$ 238,002
Potentially dilutive shares	585,766	585,766

Summary of Critical Accountin_5

Summary of Critical Accounting Policies (Percentage of Revenue by Type) (Details) - Revenue [Member]	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Internet Content Subscriptions [Member]
Product Information [Line Items]
Percentage of revenues	15.20%	43.70%
Nutritional Supplements [Member]
Product Information [Line Items]
Percentage of revenues	84.80%	56.30%

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Capital contribution from CEO's salary	$ 119,483	$ 116,442
Mr. Bezusov [Member]
Related Party Transaction [Line Items]
Consulting fees	2,000	2,500
Mr. Mannine [Member]
Related Party Transaction [Line Items]
Capital contribution from CEO's salary	116,443	$ 116,442
Expenses paid by CEO	$ 3,040

Income Taxes (Details)

Income Taxes (Details)	12 Months Ended
	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Income tax (expense) benefit	$ (1,154)	$ (1,059)
Marginal rate		0.21
Net operating loss carryforwards	1,530,000
Net operating loss carryforwards carried forward indefinitely	1,130,000
Net operating loss carryforwards expiring in 2037	407,000
Valuation allowance change	$ 92,266	$ 99,326

Income Taxes (Income Tax Rate R

Income Taxes (Income Tax Rate Reconciliation) (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Federal	21.00%	21.00%
State	3.95%	3.95%
Total taxes at blended statutory rate	24.95%	24.95%
Effect of tax rate change	0.00%	0.00%
Nondeductible expenses	0.00%	0.00%
State income tax refund	0.00%	0.00%
Other	(0.88%)	8.06%
Change in valuation allowance	(24.38%)	(33.36%)
Total income tax (benefit) expense	(0.31%)	(0.35%)

Income Taxes (Income Tax Tempor

Income Taxes (Income Tax Temporary Differences) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Federal	$ (79,480)	$ (63,411)
State	(14,950)	(10,868)
Total taxes at blended statutory rate	(94,430)	(74,279)
Effect of tax rate change
Non-deductible expenses
State income tax refund
Other	3,318	(23,988)
Change in valuation allowance	92,266	99,326
Total income tax (benefit) expense	$ 1,154	$ 1,059

Income Taxes (Deferred Tax Asse

Income Taxes (Deferred Tax Assets and Liabilities) (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 441,506	$ 347,699
Amortization of intangibles	8,317	9,149
Reserve for refunds	11	776
Stock-based compensation	3,774	3,718
Charitable contribution carryforward	3,355	3,355
Total deferred tax assets	456,963	364,697
Less: Valuation allowance	(456,963)	(364,697)
Net deferred tax assets

Notes Payable (Details)

Notes Payable (Details) - USD ($)	Dec. 17, 2020	Oct. 27, 2020	May 14, 2020	May 05, 2020	Nov. 18, 2019	Dec. 31, 2020	Dec. 31, 2019
Note Payable November 18, 2019 Individual One [Member]
Note payable					$ 50,000
Interest rate					5.00%
Term					due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.
Accrued interest						$ 1,510	$ 295
Interest paid			$ 1,250
Note Payable November 18, 2019 Individual Two [Member]
Note payable					$ 25,000
Interest rate					5.00%
Term					due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.
Accrued interest						1,380	$ 1,072
PPP Loan [Member]
Note payable				$ 27,000
Interest rate				1.00%
Term				payable monthly commencing on October 20, 2020. The loan is forgivable if the proceeds are used for eligible purposes. The Company intends to use the entire loan amount for qualifying expenses.
Note Payable October 27, 2020 [Member]
Note payable		$ 10,000
Interest rate		5.00%
Term		due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first
Accrued interest						90
Note Payable December 17, 2020 [Member]
Note payable	$ 19,500
Interest rate	5.00%
Term	due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first
Accrued interest						$ 40

Economic Injury Disaster Loan (

Economic Injury Disaster Loan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Other Income and Expenses [Abstract]
Other income	$ 2,000

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Jun. 30, 2020	Feb. 12, 2020	Jun. 14, 2018	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Other Commitments [Line Items]
Options issued
Exercise price
Capital contribution from CEO's salary					$ 119,483	$ 116,442
Stock-based compensation					39,599	571
Prepaid					13,206	3,081
Primoris Group Inc [Member]
Other Commitments [Line Items]
Issued		200,000
Fair value	$ 45,000			$ 45,000
Offering price		$ 0.225
Stock-based compensation					39,375
Shares restricted		100,000
Prepaid					5,625
Consulting fee payable					8,000
Mr. Mannine [Member]
Other Commitments [Line Items]
Annual base salary			$ 130,000
Options issued			100,000
Exercise price			$ 0.225
Capital contribution from CEO's salary					$ 116,443	$ 116,442

Stockholders' Equity (Deficit_2

Stockholders' Equity (Deficit) (Details) - USD ($)	Jun. 30, 2020	Feb. 12, 2020	Jun. 14, 2018	Mar. 08, 2018	Oct. 10, 2017	Jan. 31, 2018	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Class of Stock [Line Items]
Preferred stock, par value								$ 0.0001	$ 0.0001
Preferred stock, shares authorized								5,000,000	5,000,000
Preferred stock, share issued								0	0
Preferred stock, shares outstanding								0	0
Common stock, par value								$ 0.0001	$ 0.0001
Common stock, shares authorized								50,000,000	50,000,000
Common stock, shares issued								11,599,830	11,399,830
Common stock, shares outstanding								11,599,830	11,399,830
Capital contribution from CEO's salary								$ 119,483	$ 116,442
Prepaid								13,206	3,081
Stock-based compensation								39,599	571
Mr. Mannine [Member]
Class of Stock [Line Items]
Capital contribution from CEO's salary								116,443	$ 116,442
Volatility			45.00%
Risk free interest rate			2.20%
Expected life			10 years
Expenses paid by CEO								3,040
Warrant [Member]
Class of Stock [Line Items]
Intrinsic value outstanding								144,662
Intrinsic value exercisable								$ 144,662
CRG [Member] | Warrant [Member]
Class of Stock [Line Items]
Issued					368,111	17,655
Term					P5Y
Exercise price					$ 0.225	$ 0.225
Fair value					$ 34,405	$ 1,670
Offering price					$ 0.225	$ 0.225
Volatility					45.00%	45.00%
Risk free interest rate					2.20%	2.51%
Expected life					5 years	5 years
Scientific Advisor [Member] | Warrant [Member]
Class of Stock [Line Items]
Issued				100,000
Term				P5Y
Exercise price				$ 0.90
Vested								100,000	66,666
Fair value				$ 1,905
Offering price				$ 0.225
Volatility				45.00%
Risk free interest rate				2.63%
Expected life				5 years
Stock-based compensation								$ 224	$ 571
Primoris Group Inc [Member]
Class of Stock [Line Items]
Prepaid								5,625
Shares restricted		100,000
Issued		200,000
Fair value	$ 45,000						$ 45,000
Offering price		$ 0.225
Stock-based compensation								$ 39,375

Stockholders' Equity (Deficit_3

Stockholders' Equity (Deficit) (Information About Warrants Earned and Outstanding) (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Outstanding, beginning of year	485,766	485,766
Granted
Exercised
Forfeited
Expired
Outstanding, end of year	485,766	485,766
Exercisable, end of year	485,766	452,432
Outstanding, beginning of year	$ 0.364	$ 0.364
Granted
Exercised
Forfeited
Expired
Outstanding, end of year	0.364	0.364
Exercisable, end of year	$ 0.364	$ 0.324

Stockholders' Equity (Deficit_4

Stockholders' Equity (Deficit) (Warrants Outstanding by Price Range) (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Range of exercise price, low	$ 0.225	$ 0.225
Range of exercise price, high	$ 0.90	$ 0.90
Number outstanding	485,766	485,766
Remaining Average Contractual Life	2 years 1 month 6 days	4 years 1 month 13 days
Weighted Average Exercise Price, Outstanding	$ 0.364	$ 0.364
Number exercisable	485,766	452,432
Weighted average exercise price, exercisable	$ 0.364	$ 0.324

Stock Option Plan (Details)

Stock Option Plan (Details) - USD ($)	Jun. 14, 2018	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total awards reserved		1,100,000
Options issued
Exercise price
Intrinsic value outstanding		$ 37,500
Intrinsic value exercisable		$ 37,500
Mr. Mannine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued	100,000
Exercise price	$ 0.225
Options fair value	$ 13,221
Expected volatility	45.00%
Dividend yield	0.00%
Risk free rate	2.20%
Expected term	10 years

Stock Option Plan (Stock Option

Stock Option Plan (Stock Options Outstanding) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Outstanding, beginning of year	100,000	100,000
Granted
Exercised
Forfeited
Expired
Outstanding, end of year	100,000	100,000
Exercisable, end of year	100,000	100,000
Options available for future grant, end of year	1,000,000	1,000,000
Outstanding, beginning of year	$ 0.225	$ 0.225
Granted
Exercised
Forfeited
Expired
Outstanding, end of year	0.225	0.225
Exercisable	$ 0.225	$ 0.225

Stock Option Plan (Stock Opti_2

Stock Option Plan (Stock Options Outstanding by Exercise Price) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Range of Exercise Price, low	$ 0.225	$ 0.225
Range of Exercise Price, high	$ 0.225	$ 0.225
Number Outstanding	100,000	100,000
Remaining Average Contractual Life	7 years 11 months 4 days	8 years 6 months 14 days
Weighted Average Exercise Price	$ 0.225	$ 0.225
Number Exercisable	100,000	100,000
Exercisable Weighted Average Exercise Price	$ 0.225	$ 0.225

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	Mar. 16, 2021	Feb. 03, 2021
Note Payable February 3, 2021 [Member]
Note payable		$ 10,000
Interest rate		5.00%
Term		due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.
Note Payable March 16, 2021 [Member]
Note payable	$ 15,000
Interest rate	5.00%
Term	due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.